Tickerlog
NASDAQ
$20.81
-30.027
-2.003
Updated Saturday 2nd of April 2022 03:35:13 PM

Adicet Bio Inc. Common Stock

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
EBITDA $
ROE -30.027
EPS -2.003
Marketcap$796.3M
Free Cash Flow$
Health Care
Biotechnology: Pharmaceutical Preparations

Top gainers today
Top losers today